NO854392L - Fremgangsmaate ved fremstilling av 3-amino-2,3-dihydro-1-benzoxepin-derivater. - Google Patents
Fremgangsmaate ved fremstilling av 3-amino-2,3-dihydro-1-benzoxepin-derivater.Info
- Publication number
- NO854392L NO854392L NO854392A NO854392A NO854392L NO 854392 L NO854392 L NO 854392L NO 854392 A NO854392 A NO 854392A NO 854392 A NO854392 A NO 854392A NO 854392 L NO854392 L NO 854392L
- Authority
- NO
- Norway
- Prior art keywords
- lower alkyl
- denotes hydrogen
- group
- compounds
- halogen
- Prior art date
Links
- GOQVPHDULWKVKE-UHFFFAOYSA-N 2,3-dihydro-1-benzoxepin-3-amine Chemical class C1=CC(N)COC2=CC=CC=C21 GOQVPHDULWKVKE-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 38
- 239000001257 hydrogen Substances 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 32
- 150000002367 halogens Chemical class 0.000 claims abstract description 17
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 16
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 16
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- 125000003277 amino group Chemical group 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- DKCMLUGVNDXSDD-UHFFFAOYSA-N n-methyl-2,3-dihydro-1-benzoxepin-3-amine Chemical compound C1=CC(NC)COC2=CC=CC=C21 DKCMLUGVNDXSDD-UHFFFAOYSA-N 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000007858 starting material Substances 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 7
- 230000001430 anti-depressive effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229960005333 tetrabenazine Drugs 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 6
- MUZPHQWEBODJTH-UHFFFAOYSA-N 3-amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ol Chemical class OC1CC(N)COC2=CC=CC=C21 MUZPHQWEBODJTH-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- -1 for example Chemical group 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002631 hypothermal effect Effects 0.000 description 3
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 3
- IAYBRKMKVGEUDZ-UHFFFAOYSA-N n-methyl-2,3-dihydro-1-benzoxepin-3-amine;hydrochloride Chemical compound Cl.C1=CC(NC)COC2=CC=CC=C21 IAYBRKMKVGEUDZ-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- IJHLJYUCCGGECZ-UHFFFAOYSA-N 1-benzoxepin-5-ol;hydrochloride Chemical compound Cl.OC1=CC=COC2=CC=CC=C12 IJHLJYUCCGGECZ-UHFFFAOYSA-N 0.000 description 1
- XLHBVMMNULTPHQ-UHFFFAOYSA-N 3-(butylamino)-2,3,4,5-tetrahydro-1-benzoxepin-5-ol;hydrochloride Chemical compound Cl.OC1CC(NCCCC)COC2=CC=CC=C21 XLHBVMMNULTPHQ-UHFFFAOYSA-N 0.000 description 1
- JWUPWOYNGNTOKD-UHFFFAOYSA-N 3-(methylamino)-2,3,4,5-tetrahydro-1-benzoxepin-5-ol Chemical compound OC1CC(NC)COC2=CC=CC=C21 JWUPWOYNGNTOKD-UHFFFAOYSA-N 0.000 description 1
- WCDHGUIVSKAJDW-UHFFFAOYSA-N 3-(methylamino)-2,3,4,5-tetrahydro-1-benzoxepin-5-ol;hydrochloride Chemical compound Cl.OC1CC(NC)COC2=CC=CC=C21 WCDHGUIVSKAJDW-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- KADXIUUHHDWJLH-UHFFFAOYSA-N n,7,8-trimethyl-2,3-dihydro-1-benzoxepin-3-amine Chemical compound C1=CC(NC)COC2=CC(C)=C(C)C=C21 KADXIUUHHDWJLH-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IKGMYJIGCYUOHU-UHFFFAOYSA-N n-butyl-2,3-dihydro-1-benzoxepin-3-amine;hydrochloride Chemical compound Cl.C1=CC(NCCCC)COC2=CC=CC=C21 IKGMYJIGCYUOHU-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843440296 DE3440296A1 (de) | 1984-11-05 | 1984-11-05 | 3-amino-2,3-dihydro-1-benzoxepin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO854392L true NO854392L (no) | 1986-05-06 |
Family
ID=6249484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO854392A NO854392L (no) | 1984-11-05 | 1985-11-04 | Fremgangsmaate ved fremstilling av 3-amino-2,3-dihydro-1-benzoxepin-derivater. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4672062A (it) |
| EP (1) | EP0180889B1 (it) |
| JP (1) | JPH0641461B2 (it) |
| AT (1) | ATE43839T1 (it) |
| AU (1) | AU579416B2 (it) |
| CA (1) | CA1254893A (it) |
| DD (1) | DD238049A5 (it) |
| DE (2) | DE3440296A1 (it) |
| DK (1) | DK506885A (it) |
| ES (1) | ES8606325A1 (it) |
| FI (1) | FI854343A (it) |
| GR (1) | GR852638B (it) |
| HU (1) | HU194205B (it) |
| IL (1) | IL76936A (it) |
| NO (1) | NO854392L (it) |
| NZ (1) | NZ214066A (it) |
| PH (1) | PH22384A (it) |
| PT (1) | PT81422B (it) |
| ZA (1) | ZA858376B (it) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2582154B1 (fr) * | 1984-11-16 | 1989-03-17 | Canon Kk | Dispositif d'emission de faisceaux multiples comportant des elements semiconducteurs en particulier des diodes lasers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1593760A1 (de) * | 1967-02-01 | 1972-06-08 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung neuer Benz-epinderivate |
| DE2931399A1 (de) * | 1979-08-02 | 1981-02-26 | Kali Chemie Pharma Gmbh | Neue 3-amino-1-benzoxepin-derivate und ihre salze, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE2931398A1 (de) * | 1979-08-02 | 1981-02-26 | Kali Chemie Pharma Gmbh | Neue 1-benzoxepin-5(2h)-on-derivate und ihre salze, verfahren und zwischenprodukte zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE3440295A1 (de) * | 1984-11-05 | 1986-05-15 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Verfahren zur diastereoselektiven reduktion von 3-amino-1-benzoxepin-5(2h)-onen |
-
1984
- 1984-11-05 DE DE19843440296 patent/DE3440296A1/de not_active Withdrawn
-
1985
- 1985-10-28 AT AT85113699T patent/ATE43839T1/de not_active IP Right Cessation
- 1985-10-28 PH PH32985A patent/PH22384A/en unknown
- 1985-10-28 DE DE8585113699T patent/DE3570877D1/de not_active Expired
- 1985-10-28 EP EP85113699A patent/EP0180889B1/de not_active Expired
- 1985-10-31 ZA ZA858376A patent/ZA858376B/xx unknown
- 1985-10-31 PT PT81422A patent/PT81422B/pt unknown
- 1985-11-01 GR GR852638A patent/GR852638B/el unknown
- 1985-11-01 DD DD85282372A patent/DD238049A5/de unknown
- 1985-11-01 HU HU854192A patent/HU194205B/hu not_active IP Right Cessation
- 1985-11-04 AU AU49346/85A patent/AU579416B2/en not_active Ceased
- 1985-11-04 NO NO854392A patent/NO854392L/no unknown
- 1985-11-04 DK DK506885A patent/DK506885A/da not_active Application Discontinuation
- 1985-11-04 IL IL76936A patent/IL76936A/xx unknown
- 1985-11-04 ES ES548497A patent/ES8606325A1/es not_active Expired
- 1985-11-04 US US06/794,761 patent/US4672062A/en not_active Expired - Fee Related
- 1985-11-05 CA CA000494616A patent/CA1254893A/en not_active Expired
- 1985-11-05 FI FI854343A patent/FI854343A/fi not_active IP Right Cessation
- 1985-11-05 JP JP60246463A patent/JPH0641461B2/ja not_active Expired - Lifetime
- 1985-11-05 NZ NZ214066A patent/NZ214066A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT81422B (en) | 1987-07-31 |
| DE3570877D1 (en) | 1989-07-13 |
| NZ214066A (en) | 1988-04-29 |
| FI854343A (fi) | 1986-05-06 |
| PT81422A (en) | 1985-11-01 |
| ES548497A0 (es) | 1986-03-16 |
| DD238049A5 (de) | 1986-08-06 |
| IL76936A (en) | 1989-01-31 |
| JPH0641461B2 (ja) | 1994-06-01 |
| HU194205B (en) | 1988-01-28 |
| ATE43839T1 (de) | 1989-06-15 |
| AU579416B2 (en) | 1988-11-24 |
| FI854343A0 (fi) | 1985-11-05 |
| HUT39173A (en) | 1986-08-28 |
| ZA858376B (en) | 1986-07-30 |
| DK506885A (da) | 1986-05-06 |
| US4672062A (en) | 1987-06-09 |
| CA1254893A (en) | 1989-05-30 |
| ES8606325A1 (es) | 1986-03-16 |
| PH22384A (en) | 1988-08-12 |
| DE3440296A1 (de) | 1986-05-15 |
| AU4934685A (en) | 1986-05-15 |
| EP0180889A2 (de) | 1986-05-14 |
| EP0180889B1 (de) | 1989-06-07 |
| DK506885D0 (da) | 1985-11-04 |
| IL76936A0 (en) | 1986-04-29 |
| EP0180889A3 (en) | 1987-08-19 |
| JPS61178979A (ja) | 1986-08-11 |
| GR852638B (it) | 1986-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20040079987A (ko) | 클로피도그렐 히드로클로라이드의 다형체 및 이의 항혈전화합물로서의 용도 | |
| KR20100087300A (ko) | 글리코겐 포스포릴라아제 억제제 화합물 및 이의 약학적 조성물 | |
| JP2005232179A (ja) | ３−フェニルスルホニル−３，７−ジアザビシクロ［３，３，１］ノナン−化合物を含有する抗不整脈剤 | |
| JP2010505747A (ja) | Ａ２ａアデノシンレセプタの選択的アンタゴニスト | |
| BG64390B1 (bg) | Карбоцикличен нуклеозиден хемисулфат и неговото използване при лечението на вирусни инфекции | |
| RU2343152C2 (ru) | Замещенные дикетопиперазины и их использование в качестве антагонистов окситоцина | |
| EP0163537A1 (en) | 1-Propanone derivatives and pharmaceutical compositions containing same | |
| FR2530632A1 (fr) | Nouveaux derives substitues du 2,5-diamino 1,4-diazole, leurs procedes de preparation et les compositions pharmaceutiques en renfermant | |
| TW200523259A (en) | Amidomethyl-substituierte 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-ylderivate, verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| NO854392L (no) | Fremgangsmaate ved fremstilling av 3-amino-2,3-dihydro-1-benzoxepin-derivater. | |
| CN107793350B (zh) | 芳乙基哌啶基衍生物及其治疗精神分裂症的应用 | |
| HU198055B (en) | Process for producing n-benzofuroquinolizinyl sulfonamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
| JPS6344749B2 (it) | ||
| KR20150056544A (ko) | 쿠마린 유도체 | |
| CA1278572C (en) | Ameliorant of cerebral circulation and metabolism | |
| KR100503518B1 (ko) | 2-(4-알킬-1-피페라지닐)-벤즈알데하이드 및 -벤질리데닐화합물의 제조 방법 | |
| JPH06116273A (ja) | 三環系化合物 | |
| KR101651994B1 (ko) | 아릴옥시 아제티딘 화합물, 및 이를 포함하는 약학 조성물 | |
| JPH10237028A (ja) | Ｎｏｓ阻害作用を有する芳香族アミン誘導体 | |
| US3686217A (en) | 2-aryl-2,3,4,5-tetrahydro-1,4-benzoxazepines | |
| JPH08109177A (ja) | シクロアルキルアルキルアミン誘導体およびその用途 | |
| KR800001144B1 (ko) | 2-(4-페닐-4-시아노부틸)-1,2,3,4-테트라하이드로-5(H)-피리도-[4,3-b]-인돌의 제조방법 | |
| US3919311A (en) | 3A,12B-Dihydro-8H-dibenzo{8 3,4,6,7{9 cyclohept{8 1,2-d{9 oxazol-8-ones and process for their preparation | |
| US3584004A (en) | Substituted 1,2,5-thiadiazolidine-1-oxides and methods of preparation | |
| KR20140120903A (ko) | 여포 자극 호르몬수용체의 아고니스트로서 중수소화 티아졸리디논 유사체 |